Literature DB >> 15181979

Neuropeptide Y and Y2-receptor are involved in development of diabetic retinopathy and retinal neovascularization.

Markku Koulu1, Sharareh Movafagh, Jukka Tuohimaa, Ulriikka Jaakkola, Jaana Kallio, Ullamari Pesonen, Yixun Geng, Matti K Karvonen, Elina Vainio-Jylhä, Matti Pöllönen, Katja Kaipio-Salmi, Helena Seppälä, Edward W Lee, Rosemary D Higgins, Zofia Zukowska.   

Abstract

BACKGROUND: Neuropeptide Y is a sympathetic neurotransmitter, a potent endothelium-derived angiogenic factor and a vascular mitogen. We have studied the role of the functional leucine7 to proline7 polymorphism of the signal peptide region of preproneuropeptide Y (prepro-NPY) as a genetic susceptibility factor for diabetic retinopathy. In addition, we investigated the role of the NPY Y2-receptor as a putative mediator of angiogenic NPY signaling in the retina.
METHODS: Frequencies of proline7 (Pro7) carriers in the prepro-NPY were determined in type 1 and type 2 diabetes patients having retinopathy, in type 2 diabetes patients without retinopathy and in healthy control subjects. The role of Y2-receptor in hyperoxemia-induced retinal neovascularization was investigated in Y2-receptor knockout mice (Y2-/-) and in rats administered Y2-receptor mRNA antisense oligonucleotide.
RESULTS: The carriers having Pro7 in the preproNPY are markedly over-represented among type 2 diabetes patients with retinopathy compared to type 2 diabetes patients without retinopathy and to the population control. Neonatal exposure to hyperoxia resulted in development of retinal neovascularization that was prevented in Y2(-1-) -mice, and significantly inhibited in rats treated with the Y2-receptor antisense oligonucleotide.
CONCLUSIONS: NPY and Y2-receptor play important roles in diabetic retinopathy and retinal neovascularization and are thus potential new targets for drug molecules for treatment of retinopathy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15181979     DOI: 10.1080/07853890410031236

Source DB:  PubMed          Journal:  Ann Med        ISSN: 0785-3890            Impact factor:   4.709


  21 in total

1.  Position and length of fatty acids strongly affect receptor selectivity pattern of human pancreatic polypeptide analogues.

Authors:  Veronika Mäde; Kathrin Bellmann-Sickert; Anette Kaiser; Jens Meiler; Annette G Beck-Sickinger
Journal:  ChemMedChem       Date:  2014-08-22       Impact factor: 3.466

Review 2.  NPY and stress 30 years later: the peripheral view.

Authors:  Dalay Hirsch; Zofia Zukowska
Journal:  Cell Mol Neurobiol       Date:  2012-01-24       Impact factor: 5.046

Review 3.  [Viral and nonviral gene therapy for treatment of retinal diseases].

Authors:  J Neidhardt; K Wycisk; B Klöckener-Gruissem
Journal:  Ophthalmologe       Date:  2005-08       Impact factor: 1.059

4.  Maternal low-protein diet up-regulates the neuropeptide Y system in visceral fat and leads to abdominal obesity and glucose intolerance in a sex- and time-specific manner.

Authors:  Ruijun Han; Aiyun Li; Lijun Li; Joanna B Kitlinska; Zofia Zukowska
Journal:  FASEB J       Date:  2012-04-25       Impact factor: 5.191

Review 5.  Neuropeptide Y Y2 receptor in health and disease.

Authors:  S L Parker; A Balasubramaniam
Journal:  Br J Pharmacol       Date:  2007-09-10       Impact factor: 8.739

6.  Vital exhaustion and retinal microvascular changes in cardiovascular disease: atherosclerosis risk in communities study.

Authors:  Ning Cheung; Sophie Rogers; Thomas H Mosley; Ronald Klein; David Couper; Tien Y Wong
Journal:  Psychosom Med       Date:  2008-12-10       Impact factor: 4.312

Review 7.  Stress, NPY and vascular remodeling: Implications for stress-related diseases.

Authors:  Lydia E Kuo; Ken Abe; Zofia Zukowska
Journal:  Peptides       Date:  2007-01-22       Impact factor: 3.750

8.  Sympathetic Neurotransmitters and Tumor Angiogenesis-Link between Stress and Cancer Progression.

Authors:  Jason Tilan; Joanna Kitlinska
Journal:  J Oncol       Date:  2010-05-20       Impact factor: 4.375

9.  Neuropeptide Y and its Y2 receptor: potential targets in neuroblastoma therapy.

Authors:  C Lu; L Everhart; J Tilan; L Kuo; C-C J Sun; R B Munivenkatappa; A-C Jönsson-Rylander; J Sun; A Kuan-Celarier; L Li; K Abe; Z Zukowska; J A Toretsky; J Kitlinska
Journal:  Oncogene       Date:  2010-08-02       Impact factor: 9.867

10.  Sympathetic nervous system-targeted neuropeptide Y overexpression in mice enhances neointimal formation in response to vascular injury.

Authors:  Suvi T Ruohonen; Ken Abe; Mia Kero; Laura Toukola; Saku Ruohonen; Matias Röyttä; Markku Koulu; Ullamari Pesonen; Zofia Zukowska; Eriika Savontaus
Journal:  Peptides       Date:  2008-12-24       Impact factor: 3.750

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.